company background image
SIGHT logo

GenSight Biologics ENXTPA:SIGHT Stock Report

Last Price

€0.40

Market Cap

€31.2m

7D

-14.1%

1Y

-81.0%

Updated

26 Mar, 2024

Data

Company Financials +

GenSight Biologics S.A.

ENXTPA:SIGHT Stock Report

Market Cap: €31.2m

SIGHT Stock Overview

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.

SIGHT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

GenSight Biologics S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for GenSight Biologics
Historical stock prices
Current Share Price€0.40
52 Week High€2.53
52 Week Low€0.30
Beta2.14
1 Month Change0%
3 Month Change-12.57%
1 Year Change-81.04%
3 Year Change-94.31%
5 Year Change-79.40%
Change since IPO-95.09%

Recent News & Updates

Recent updates

Is There An Opportunity With GenSight Biologics S.A.'s (EPA:SIGHT) 30% Undervaluation?

Dec 22
Is There An Opportunity With GenSight Biologics S.A.'s (EPA:SIGHT) 30% Undervaluation?

Is GenSight Biologics S.A. (EPA:SIGHT) Trading At A 39% Discount?

Sep 20
Is GenSight Biologics S.A. (EPA:SIGHT) Trading At A 39% Discount?

Health Check: How Prudently Does GenSight Biologics (EPA:SIGHT) Use Debt?

Aug 17
Health Check: How Prudently Does GenSight Biologics (EPA:SIGHT) Use Debt?

Rock star Growth Puts GenSight Biologics (EPA:SIGHT) In A Position To Use Debt

Aug 04
Rock star Growth Puts GenSight Biologics (EPA:SIGHT) In A Position To Use Debt

GenSight Biologics S.A. (EPA:SIGHT) Shares Could Be 27% Below Their Intrinsic Value Estimate

Jun 14
GenSight Biologics S.A. (EPA:SIGHT) Shares Could Be 27% Below Their Intrinsic Value Estimate

GenSight Biologics S.A. (EPA:SIGHT): Is Breakeven Near?

May 10
GenSight Biologics S.A. (EPA:SIGHT): Is Breakeven Near?

Analysts Expect Breakeven For GenSight Biologics S.A. (EPA:SIGHT) Before Long

Feb 02
Analysts Expect Breakeven For GenSight Biologics S.A. (EPA:SIGHT) Before Long

A Quick Analysis On GenSight Biologics' (EPA:SIGHT) CEO Salary

Dec 09
A Quick Analysis On GenSight Biologics' (EPA:SIGHT) CEO Salary

Shareholder Returns

SIGHTFR BiotechsFR Market
7D-14.1%-0.2%-0.4%
1Y-81.0%-1.8%10.6%

Return vs Industry: SIGHT underperformed the French Biotechs industry which returned -2.2% over the past year.

Return vs Market: SIGHT underperformed the French Market which returned 10.1% over the past year.

Price Volatility

Is SIGHT's price volatile compared to industry and market?
SIGHT volatility
SIGHT Average Weekly Movement11.2%
Biotechs Industry Average Movement5.8%
Market Average Movement4.3%
10% most volatile stocks in FR Market10.0%
10% least volatile stocks in FR Market2.2%

Stable Share Price: SIGHT has not had significant price volatility in the past 3 months.

Volatility Over Time: SIGHT's weekly volatility has decreased from 21% to 11% over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
201223Laurence Rodriguezhttps://www.gensight-biologics.com

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration.

GenSight Biologics S.A. Fundamentals Summary

How do GenSight Biologics's earnings and revenue compare to its market cap?
SIGHT fundamental statistics
Market cap€31.24m
Earnings (TTM)-€28.87m
Revenue (TTM)€3.33m

9.4x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SIGHT income statement (TTM)
Revenue€3.33m
Cost of Revenue€0
Gross Profit€3.33m
Other Expenses€32.20m
Earnings-€28.87m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.37
Gross Margin100.00%
Net Profit Margin-867.06%
Debt/Equity Ratio-74.6%

How did SIGHT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.